Antibiotics Deals are Blossoming
Executive Summary
Biotech has joined the new war on infectious diseases-for sound business reasons.
You may also be interested in...
Getting the Bugs Out of Antibiotic R&D: Commercial Implications of a Higher Regulatory Hurdle
It's a gloomy time for antibiotic R&D: higher regulatory hurdles and commercial challenges have forced many companies to leave the market. But a few major players and boutique firms remain committed to the field. What do they see that the rest of the industry is overlooking?
ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?
AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
ASCO 2023 – Pfizer Pushes Forward In Drug-Resistant Breast Cancer
While Ibrance has been bested by class rivals Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance, although it is not alone.